Group 1 - The core point of the article is that Shenzhen MicuRx Pharmaceuticals Co., Ltd. and Chengdu MicuRx Pharmaceuticals Co., Ltd. have initiated a Phase III clinical trial for the drug Xioroni in combination with PD-1 monoclonal antibody, albumin-bound paclitaxel, and gemcitabine for the first-line treatment of metastatic pancreatic ductal adenocarcinoma patients [1][2] - The clinical trial aims to evaluate the safety and tolerability of Xioroni in combination with chemotherapy during the induction phase, and the efficacy of the combination regimen during the randomized controlled phase [1] - The trial has a target enrollment of 558 participants and is currently ongoing, with the clinical trial registration number CTR20260141 and the first public information date set for January 15, 2026 [1][2] Group 2 - The primary endpoints of the trial include the incidence and severity of adverse events during the induction phase and overall survival (OS) during the randomized controlled phase [2] - Secondary endpoints encompass various measures such as objective response rate (ORR), duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), and quality of life (QoL) assessments [2] - The drug Xioroni is a chemical medication indicated for metastatic pancreatic ductal adenocarcinoma, a malignancy characterized by high metastatic potential and poor prognosis [1][2]

证券代码：688321 证券简称：微芯生物 公告编号：2026-006 深圳微芯生物科技股份有限公司 关于 2026 年度日常关联交易额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●深圳微芯生物科技股份有限公司（以下简称"公司"）本次预计 2026 年 度日常关联交易额度（以下简称"本次预计事项"）系为满足公司正常生产经营 需要，相关日常关联交易遵循公允、合理的原则，不存在损害公司及股东利益的 情形，不影响公司独立性，公司不会因此对关联人形成较大的依赖。 ●本次预计事项已经公司第三届董事会第二十次会议审议通过，无需提交公 司股东会审议。 一、 日常关联交易基本情况 (一) 日常关联交易履行的审议程序 1、公司独立董事专门会议审议程序 公司已于 2026 年 1 月 15 日召开了第三届董事会独立董事专门会议 2026 年 第一次会议，审议通过了《关于 2026 年度日常关联交易额度预计的议案》，并 经公司全体独立董事一致同意，形成以下意见：公司预计 2026 年度日常关联交 易额度是基于公 ...

股票简称：微芯生物 股票代码：688321 深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票募集说明书 深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票 募集说明书 （注册稿） 保荐机构（主承销商） （深圳市福田区福田街道福华一路119号安信金融大厦） 二〇二五年十月 深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票募集说明书 声 明 本公司及全体董事、监事、高级管理人员承诺本募集说明书内容真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承 担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证券监督管理委员会、上海证券交易所对本次发行所作的任何决定或意 见，均不表明其对申请文件及所披露信息的真实性、准确性、完整性作出保证， 也不表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断 或保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价 ...

Core Viewpoint - The A-share market is experiencing a significant upward trend, with the Shanghai Composite Index returning to 4100 points for the first time in 10 years, driven by a strong performance in the innovative pharmaceutical sector, particularly the Sci-Tech Innovation Drug ETF Huatai (589120) which rose over 3% [1] Group 1: Market Performance - The Sci-Tech Innovation Drug ETF Huatai (589120) saw most of its constituent stocks surge, with notable increases such as Yuekang Pharmaceutical up over 10%, Zhixiang Jintai up over 8%, and Micron Biologics up over 6% [3] - The top ten constituent stocks of the ETF include major players in the pharmaceutical sector, with BeiGene (688235) rising by 1.77% and Aier Eye Hospital (688578) increasing by 2.18% [3] Group 2: Regulatory Support - A national drug supervision conference held from January 6 to 7 emphasized the need to actively support the pharmaceutical industry in enhancing quality and efficiency, alongside comprehensive reforms in drug regulation [4] Group 3: Innovation and Drug Approvals - Innovation remains a key theme in the Sci-Tech Innovation Drug sector, with recent announcements including Zhixiang Jintai's conditional listing application for a dual-antibody drug and Micron Biologics receiving approval for clinical trials of a new drug for pancreatic cancer [5] - BeiGene announced the conditional approval of its new BCL2 inhibitor, providing new treatment options for patients with chronic lymphocytic leukemia [6] - Rongchang Biologics is seeking breakthrough therapy designation for a new indication of its drug, which would mark a significant regulatory achievement for domestic ADC products [7] Group 4: Future Outlook - The Pacific Securities report anticipates that by 2026, the innovative drug sector will benefit from enhanced international capabilities and supportive industry policies, leading to increased market confidence and investment [8] - The report highlights that the average deal value for innovative drugs purchased from China by top multinational corporations is significantly higher than those from overseas, indicating a growing recognition of the value of Chinese innovative drugs in the global market [9]

Core Viewpoint - Microchip Biotech has received approval from the National Medical Products Administration for clinical trials of its product, Sioroni Capsules [2] Group 1 - The company announced the receipt of the "Drug Clinical Trial Approval Notification" [2] - The approval allows the company to commence clinical trials for Sioroni Capsules [2]

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]

Core Viewpoint - Microchip Biotech (688321.SH) has received approval from the National Medical Products Administration for clinical trials of its product, Xioroni Capsules, in combination with Tislelizumab and chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma [1] Group 1 - The company has been granted a Clinical Trial Approval Notice for its product [1] - The clinical research will focus on the treatment of metastatic pancreatic ductal adenocarcinoma [1] - The study will involve a combination therapy approach, utilizing both Xioroni Capsules and Tislelizumab alongside chemotherapy [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its new anti-tumor drug, Xioroni, which is expected to show significant efficacy in treating pancreatic cancer [1][2]. Group 1: Drug Development - The company has developed Xioroni, a novel small molecule anti-tumor drug with a unique chemical structure, which has global intellectual property protection [1]. - Xioroni exhibits a multi-pathway anti-tumor mechanism by inhibiting multiple kinase targets such as AuroraB, CSF1R, and VEGFR/PDGFR/c-Kit, demonstrating comprehensive anti-pancreatic cancer effects [1]. Group 2: Clinical Trial Results - Phase II clinical trial data indicates that Xioroni combined with standard AG chemotherapy (albumin-bound paclitaxel and gemcitabine) shows better objective response rates, disease control rates, and progression-free survival compared to historical data of AG chemotherapy [2]. - The safety and tolerability of Xioroni in patients have been reported as good, suggesting a favorable profile for further development [2]. Group 3: Future Expectations - The company anticipates that combining Xioroni with PD-1 monoclonal antibodies and chemotherapy will further improve clinical efficacy and extend survival time for patients with advanced pancreatic cancer [2].

申请人：深圳微芯生物科技股份有限公司、成都微芯药业有限公司 证券代码：688321 证券简称：微芯生物 公告编号：2026-005 深圳微芯生物科技股份有限公司 自愿披露关于西奥罗尼胶囊获得药物临床试验批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳微芯生物科技股份有限公司（以下简称"公司"）近日收到国家药品监 督管理局（以下简称"国家药监局"）签发的《药物临床试验批准通知书》，同意 公司产品西奥罗尼胶囊开展临床试验。现将相关情况公告如下： 一、药品基本情况 产品名称：西奥罗尼胶囊 受理号：CXHL2501217、CXHL2501219 适应症：西奥罗尼联合 PD-1 单抗及化疗一线治疗转移性胰腺导管腺癌患者 2026 年 1 月 9 日 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 6 日受理的西奥罗尼胶囊临床试验申请符合药品注册的有关要求，同意本 品开展联合特瑞普利单抗及化疗一线治疗转移性胰腺导管腺癌的临床研究。 二、药品的其他相关情况 胰腺癌是全球公认最致命 ...

Group 1 - The core point of the article is that Microchip Biotech has received approval from the National Medical Products Administration for clinical trials of its product, Xioroni capsules, which are intended for the treatment of metastatic pancreatic ductal adenocarcinoma in combination with PD-1 monoclonal antibodies and chemotherapy [1] Group 2 - Xioroni capsules are a novel small molecule anti-tumor drug developed by the company, featuring a new chemical structure and a multi-pathway anti-tumor mechanism [1]